20 articles
A Cochrane review of 37 RCTs finds obesity drugs modestly reduce weight in adolescents, but evidence quality is low and long-term data are absent.
Longevity experts endorse short CGM trials for non-diabetics, but RCT evidence remains thin. Here's what the data actually shows.
Longevity experts endorse CGMs for metabolic optimization, but RCT evidence in non-diabetics is still thin.
A Cochrane review of 21 RCTs finds remote pharmacist care may improve adherence and lower blood pressure in NCD patients.
A landmark AHA scientific statement tackles inconsistent cardiovascular safety reporting in oncology trials with a unified framework.
A Cochrane meta-analysis of 11 RCTs finds very low-certainty evidence that liver support systems neither reduce mortality nor improve key outcomes in ALF.
A Cochrane meta-analysis of 17 RCTs finds amyloid-targeting antibodies offer minimal cognitive gains while significantly raising ARIA risk.
Continuous glucose monitors are popular in biohacking circles, but direct evidence linking CGM use to extended lifespan remains thin.
A head-to-head review of 10 CGM devices for healthy adults, weighing real-world accuracy data against limited longevity evidence.
Expert reviews of top CGM platforms reveal genuine metabolic insights — but no proof they extend lifespan in healthy adults.
Expert reviews compare top CGMs for longevity use, but evidence for healthy adults remains limited. Here's what you need to know.
Top longevity doctors endorse CGMs for healthy adults, but evidence is mixed. Here's what the 2026 device reviews reveal.
A Cochrane review of two RCTs finds very low-certainty evidence that IGF-1 neither prevents nor worsens retinopathy of prematurity in extremely preterm infants.
Six leading CGM platforms compared on accuracy, evidence quality, and longevity claims — most fall short of the hype.
Dexcom G7 tops expert picks for metabolic biohacking, but evidence for non-diabetics remains mixed. Here's what the data says.
A Cochrane meta-analysis of 8 RCTs finds most pharmacological treatments fail to improve ataxia scores, though upper limb dexterity may benefit.
A Circulation review from Harvard proposes the 'target trial framework' to improve how observational data is used to assess cardiovascular device safety and effectiveness.
A landmark review reveals how diet, gut bacteria, and their metabolites determine the success of immune checkpoint blockade cancer therapy.
A new review reframes magnesium as a master regulator of mitochondrial energy, metabolic disease, and biological aging.
A Cochrane meta-analysis of 17 RCTs finds blue light TURBT reduces bladder cancer recurrence and progression, especially in intermediate- and high-risk patients.
